CL2012000319A1 - Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística. - Google Patents

Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.

Info

Publication number: CL2012000319A1
Authority: CL; Chile
Prior art keywords: prevention; preparation; treatment; pharmaceutical composition; treprostinil
Prior art date: 2009-08-07

Application number

CL2012000319A

Other languages

English (en)

Spanish (es)

Inventor

Michael Freissmuth

Xavier Koening

Christina Gloeckel

Original Assignee

Scipharm Sarl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-08-07

Filing date

2012-02-07

Publication date

2012-09-14

2012-02-07 Application filed by Scipharm Sarl filed Critical Scipharm Sarl

2012-09-14 Publication of CL2012000319A1 publication Critical patent/CL2012000319A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CL2012000319A 2009-08-07 2012-02-07 Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística. CL2012000319A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP09167491		2009-08-07

Publications (1)

Publication Number	Publication Date
CL2012000319A1 true CL2012000319A1 (es)	2012-09-14

Family

ID=41382119

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012000319A CL2012000319A1 (es)	2009-08-07	2012-02-07	Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.

Country Status (25)

Country	Link
US (2)	US20120184622A1 (el)
EP (1)	EP2461812B1 (el)
JP (1)	JP5877787B2 (el)
KR (1)	KR101729800B1 (el)
CN (1)	CN102548559B (el)
AU (1)	AU2010280684B2 (el)
BR (1)	BR112012002578B8 (el)
CA (1)	CA2770066C (el)
CL (1)	CL2012000319A1 (el)
CY (1)	CY1114983T1 (el)
DK (1)	DK2461812T3 (el)
EA (1)	EA023720B1 (el)
ES (1)	ES2451790T3 (el)
GT (1)	GT201200038A (el)
HN (1)	HN2012000297A (el)
HR (1)	HRP20140277T1 (el)
IL (1)	IL217899B (el)
PL (1)	PL2461812T3 (el)
PT (1)	PT2461812E (el)
RS (1)	RS53234B (el)
SG (1)	SG178315A1 (el)
SI (1)	SI2461812T1 (el)
SM (1)	SMT201400057B (el)
WO (1)	WO2011015630A1 (el)
ZA (1)	ZA201200790B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8551528B2 (en)	2009-06-12	2013-10-08	Mannkind Corporation	Diketopiperazine microparticles with defined specific surface areas
PL2663313T3 (pl) *	2011-01-13	2019-01-31	SciPharm S.à r.l.	Sposób zwiększania wszczepiania hematopoetycznych komórek macierzystych
KR101852222B1 (ko)	2011-02-07	2018-04-25	에스씨아이팜 에스에이알엘	낭포성 섬유증의 치료를 위한 신규 조성물
EP3712142B1 (en)	2013-01-11	2022-07-06	Corsair Pharma, Inc.	Prodrugs of treprostinil
US9505737B2 (en)	2013-01-11	2016-11-29	Corsair Pharma, Inc.	Treprostinil derivative compounds and methods of using same
MX369136B (es)	2013-03-15	2019-10-30	Mannkind Corp	Composiciones de dicetopiperazina microcristalina y metodos.
BR122019026637B1 (pt)	2013-07-18	2023-09-26	Mannkind Corporation	Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
BR112016009207B1 (pt)	2013-10-25	2022-11-22	Insmed Incorporated	Compostos de prostaciclina
CA2967385C (en)	2014-11-18	2023-05-16	Insmed Incorporated	Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9394227B1 (en)	2015-06-17	2016-07-19	Corsair Pharma, Inc.	Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en)	2015-06-17	2017-05-09	Corsair Pharma, Inc.	Treprostinil derivatives and compositions and uses thereof
IL262720B2 (en)	2016-05-05	2024-06-01	Liquidia Tech Inc	Dry powder treprostinil for the treatment of pulmonary hypertension
EP3515430A1 (en)	2016-09-26	2019-07-31	United Therapeutics Corporation	Treprostinil prodrugs
KR20220002600A (ko)	2019-04-29	2022-01-06	인스메드 인코포레이티드	트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법
CA3149358A1 (en)	2019-08-23	2021-03-04	United Therapeutics Corporation	Treprostinil prodrugs
IL296567A (en)	2020-04-17	2022-11-01	United Therapeutics Corp	Terfostinil for use in the treatment of interstitial lung disease
US11793780B2 (en)	2020-06-09	2023-10-24	United Therapeutics Corporation	Prodrugs of treprosiinil
CN117062605A (zh)	2020-12-14	2023-11-14	联合治疗公司	使用曲前列环素前药治疗疾病的方法
CA3209987A1 (en)	2021-03-03	2022-09-09	Hitesh Batra	A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT947196E (pt) *	1997-03-14	2009-09-24	Toray Industries	Preparação de derivado de prostaglandina i de libertação prolongada
AU4976599A (en) *	1998-07-08	2000-02-01	Fibrogen, Inc.	Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
MXPA04002006A (es) *	2001-08-31	2004-06-07	Sucampo Ag	Analogos de prostagladina como abridor del canal de cloruro.
US7550133B2 (en) *	2002-11-26	2009-06-23	Alexza Pharmaceuticals, Inc.	Respiratory drug condensation aerosols and methods of making and using them
CA2959852A1 (en) *	2003-05-22	2005-01-27	United Therapeutics Corporation	Compounds and methods for delivery of prostacyclin analogs
US20040265238A1 (en) *	2003-06-27	2004-12-30	Imtiaz Chaudry	Inhalable formulations for treating pulmonary hypertension and methods of using same
US20080096915A1 (en) *	2005-01-13	2008-04-24	Greenberg Traurig LLP	Compositions for the treatment of metabolic disorders
WO2007050783A2 (en) *	2005-10-26	2007-05-03	Asahi Kasei Pharma Corporation	Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
BRPI0707488B8 (pt) *	2006-02-03	2021-05-25	Actelion One Sa	método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável
CN102648916A (zh) *	2007-02-09	2012-08-29	联合治疗公司	用于间质性肺病和哮喘的曲前列尼治疗

2010
- 2010-08-05 BR BR112012002578A patent/BR112012002578B8/pt not_active IP Right Cessation
- 2010-08-05 AU AU2010280684A patent/AU2010280684B2/en not_active Ceased
- 2010-08-05 HR HRP20140277AT patent/HRP20140277T1/hr unknown
- 2010-08-05 SI SI201030560T patent/SI2461812T1/sl unknown
- 2010-08-05 DK DK10739941.2T patent/DK2461812T3/da active
- 2010-08-05 SG SG2012008702A patent/SG178315A1/en unknown
- 2010-08-05 WO PCT/EP2010/061428 patent/WO2011015630A1/en not_active Ceased
- 2010-08-05 EP EP10739941.2A patent/EP2461812B1/en active Active
- 2010-08-05 US US13/389,281 patent/US20120184622A1/en not_active Abandoned
- 2010-08-05 KR KR1020127003535A patent/KR101729800B1/ko active Active
- 2010-08-05 CA CA2770066A patent/CA2770066C/en not_active Expired - Fee Related
- 2010-08-05 CN CN2010800454199A patent/CN102548559B/zh not_active Expired - Fee Related
- 2010-08-05 JP JP2012523343A patent/JP5877787B2/ja active Active
- 2010-08-05 ES ES10739941.2T patent/ES2451790T3/es active Active
- 2010-08-05 EA EA201200253A patent/EA023720B1/ru not_active IP Right Cessation
- 2010-08-05 RS RS20140134A patent/RS53234B/sr unknown
- 2010-08-05 PL PL10739941T patent/PL2461812T3/pl unknown
- 2010-08-05 PT PT107399412T patent/PT2461812E/pt unknown
2012
- 2012-02-01 ZA ZA2012/00790A patent/ZA201200790B/en unknown
- 2012-02-02 IL IL217899A patent/IL217899B/en active IP Right Grant
- 2012-02-07 CL CL2012000319A patent/CL2012000319A1/es unknown
- 2012-02-07 GT GT201200038A patent/GT201200038A/es unknown
- 2012-02-07 HN HN2012000297A patent/HN2012000297A/es unknown
2014
- 2014-03-18 CY CY20141100210T patent/CY1114983T1/el unknown
- 2014-04-29 SM SM201400057T patent/SMT201400057B/xx unknown
2015
- 2015-12-22 US US14/978,914 patent/US10086001B2/en active Active

Also Published As

Publication number	Publication date
AU2010280684B2 (en)	2016-07-28
CA2770066C (en)	2018-10-23
US10086001B2 (en)	2018-10-02
SI2461812T1 (sl)	2014-05-30
ES2451790T3 (es)	2014-03-28
SG178315A1 (en)	2012-03-29
CA2770066A1 (en)	2011-02-10
EP2461812A1 (en)	2012-06-13
PT2461812E (pt)	2014-04-07
RS53234B (sr)	2014-08-29
CY1114983T1 (el)	2016-12-14
GT201200038A (es)	2015-01-16
KR101729800B1 (ko)	2017-04-24
KR20120056819A (ko)	2012-06-04
CN102548559B (zh)	2013-12-25
US20120184622A1 (en)	2012-07-19
EP2461812B1 (en)	2014-01-01
HK1165293A1 (en)	2012-10-05
WO2011015630A1 (en)	2011-02-10
BR112012002578A2 (pt)	2016-03-15
EA023720B1 (ru)	2016-07-29
US20160175319A1 (en)	2016-06-23
EA201200253A1 (ru)	2012-07-30
JP2013501032A (ja)	2013-01-10
PL2461812T3 (pl)	2014-12-31
AU2010280684A1 (en)	2012-02-23
DK2461812T3 (da)	2014-04-07
IL217899B (en)	2018-05-31
SMT201400057B (it)	2014-07-07
CN102548559A (zh)	2012-07-04
IL217899A0 (en)	2012-03-29
ZA201200790B (en)	2013-05-29
BR112012002578B1 (pt)	2021-01-12
BR112012002578B8 (pt)	2021-05-25
HRP20140277T1 (hr)	2014-04-25
HN2012000297A (es)	2015-05-18
JP5877787B2 (ja)	2016-03-08

Similar Documents

Publication	Publication Date	Title
CL2012000319A1 (es)	2012-09-14	Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
CL2008001002A1 (es)	2008-10-17	Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
CL2008001003A1 (es)	2008-10-17	Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
AR090491A1 (es)	2014-11-19	Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
CL2016002132A1 (es)	2017-06-09	Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
DOP2010000299A (es)	2010-11-15	Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad
CL2013000481A1 (es)	2013-11-22	Metodo y para mejorar la eficacia y/o reducir los efectos secundarios de una farmacoterapia administrada de forma suboptima que comprende la administracion de un hexitol sustituido; composicion farmaceutica; combinacion farmaceutica; uso para tratar enfermedades proliferativas.
BR112012016853A2 (pt)	2017-10-17	"composições farmacêuticas para administração oral de peptídeos de insulina".
CL2012003281A1 (es)	2013-05-17	Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
TN2011000471A1 (en)	2013-03-27	Pharmaceutical composition presenting anti-inflammatory properties
UY32764A (es)	2011-01-31	Preparaciones insulinicas que comprenden metionina
BRPI1009392A2 (pt)	2016-03-08	"formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
CL2011002595A1 (es)	2013-10-04	Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
PE20140255A1 (es)	2014-03-11	Tableta dispersable en forma oral
CL2013001564A1 (es)	2014-05-02	Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica.
CL2009001841A1 (es)	2011-02-18	Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
AR073265A1 (es)	2010-10-28	Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
ECSP10010553A (es)	2010-11-30	Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
UY31887A (es)	2010-01-29	Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la cardioversión
CL2010001577A1 (es)	2011-05-06	Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
SV2010003773A (es)	2011-08-29	7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2010001594A1 (es)	2011-05-06	Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
AR067351A1 (es)	2009-10-07	Combinacion de picotamida con nafronil
AR084435A1 (es)	2013-05-15	Combinacion y composicion para el tratamiento de obesidad
CL2008003584A1 (es)	2009-05-22	Uso de la 10-[(3r)-1-azabiciclo]oct-3-ilmetil]-10-h-fenotiazina, o una de sus sales farmaceuticamente aceptables para la preparación de un medicamento util para prevenir o tratar la bronconeumopatia obstructiva.